Biotech

All Articles

AstraZeneca articles records on in-house opponents to AbbVie, Pfizer ADCs

.AstraZeneca has discussed a very early look at the efficiency of its own internal antibody-drug con...

iTeos- GSK's TIGIT superstar presents meaningful renovation

.After revealing a period 3 launch based upon positive midstage results, iTeos and also GSK are actu...

More collective FDA may speed up rare ailment R&ampD: report

.The FDA ought to be a lot more available and also collaborative to discharge a surge in approvals o...

Zenas, MBX, Bicara scalp to Nasdaq in hot day for biotech IPOs

.It's an extraordinarily active Friday for biotech IPOs, with Zenas BioPharma, MBX as well as Bicara...

Atea's COVID antiviral neglects to halt hospitalizations in period 3

.Atea Pharmaceuticals' antiviral has fallen short one more COVID-19 test, yet the biotech still stor...

Neurocrine's bid to spare schizophrenia possibility fails

.Neurocrine Biosciences' schizophrenia program pivot has failed. The biotech was not able to reprodu...

Sanofi pays for $110M upfront for late-stage radioligand treatment

.Sanofi has actually created a late entrance to the radioligand event, spending 100 million euros ($...

F 2G brings up $100M for 2nd try to get brand new antifungal to market

.After F2G's first attempt to obtain a brand-new course of antifungal to market was derailed by the ...

Moderna targets $1.1 B in R&ampD investing cuts, drops 5 programs among success pressures

.Moderna has sworn to reduce R&ampD investing by $1.1 billion through 2027. The choice to retract th...

Sanofi's $80M bet on Fulcrum dystrophy drug finishes in stage 3 fail

.Merely four months after Sanofi bet $80 million in beforehand cash on Fulcrum Rehabs' losmapimod, t...